S Frustaci
Overview
Explore the profile of S Frustaci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majo J, et al.
Ann Oncol
. 2012 Nov;
24(3):817-23.
PMID: 23110811
Background: To explore correlation between the quality of surgery and outcome in high-risk soft tissue sarcoma (STS) patients treated within a phase III randomized trial. Patients And Methods: In the...
2.
De Pas T, Rosati G, Spitaleri G, Boni C, Tucci A, Frustaci S, et al.
Chemotherapy
. 2011 May;
57(3):217-24.
PMID: 21597285
Background: Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity. A phase II trial was designed to...
3.
Berretta M, Bearz A, Frustaci S, Talamini R, Lombardi D, Fratino L, et al.
J Chemother
. 2008 Aug;
20(4):503-8.
PMID: 18676233
The effectiveness of chemotherapy in elderly patients is still a matter of debate. We analyzed the toxicity and efficacy of the original FOLFOX2 regimen in middle aged and elderly patients...
4.
Santoro A, Romanini A, Rosso A, Frustaci S, Comandone A, Apice G, et al.
Sarcoma
. 2008 Jun;
3(3-4):177-81.
PMID: 18521282
Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15- 25%. Consequently drug development seems mandatory to improve...
5.
De Paoli A, Bertola G, Boz G, Frustaci S, Massarut S, Innocente R, et al.
J Exp Clin Cancer Res
. 2006 Jun;
22(4 Suppl):157-61.
PMID: 16767923
Treatment of retroperitoneal soft tissue sarcomas is a difficult clinical problem. Despite the improvement in resection rates in the most recent surgical series, local control still remains the main problem...
6.
Berretta M, Rupolo M, Buonadonna A, Canzonieri V, Brollo A, Morra A, et al.
J Chemother
. 2006 Jun;
18(2):221-4.
PMID: 16736893
Angiosarcomas are rare soft tissue malignancies. Typically they originate from the skin of the scalp or face, whereas visceral sarcomas are very rare. We report the case of a 67-year-old...
7.
Berretta M, Bearz A, Frustaci S, Buonadonna A, La Mura N, Malaguarnera M, et al.
Ann Oncol
. 2006 May;
17(10):1606-7.
PMID: 16728481
No abstract available.
8.
De Paoli A, Chiara S, Luppi G, Friso M, Beretta G, Del Prete S, et al.
Ann Oncol
. 2005 Nov;
17(2):246-51.
PMID: 16282246
Background: The aim of the study was to evaluate tolerance and efficacy of preoperative treatment with capecitabine in combination with radiation therapy (RT) in patients with locally advanced, resectable, rectal...
9.
Berretta M, Taibi R, Bearz A, La Mura N, Berretta S, Tirelli U, et al.
J Chemother
. 2005 Feb;
16(6):595-8.
PMID: 15700853
Oxaliplatin is a new, third-generation platinum complex. It has a good safety profile characterized by low hematological-gastrointestinal toxicity. No significant nephro-ototoxicity has been observed. Acute peripheral neuropathy is a common...
10.
Gherlinzoni F, Picci P, Mercuri M, Bacci G, Frustaci S, De Paoli A, et al.
Chir Organi Mov
. 2005 Jan;
89(2):95-105.
PMID: 15645786
The authors take into consideration all types of treatment used at the Rizzoli Orthopaedic Institute and in associated centers over the last 40 years for soft tissue sarcoma of the...